iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that the Company will release financial results for the three and six months ended September 30, 2011, following the close of the market on Wednesday, October 26, 2011.
Ken Ferry, President and Chief Executive Officer, and Kevin C. Burns, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern time on Thursday, October 27, 2011 to discuss the third quarter 2011 financial results and to answer questions.
Shareholders and other interested parties may participate in the conference call by dialing 800-299-0148 (domestic) or 617-801-9711 (international) and entering passcode 12967438 a few minutes before 10:00 a.m. ET on Thursday, October 27, 2011. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.
A replay of the conference call will be accessible two hours after its completion through November 1, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 74124094. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.About iCAD iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent ® eBx™ electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit www.icadmed.com. For iCAD, contact Kevin Burns at 603-882-5200 x7967, or via email at firstname.lastname@example.org For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-8383777 x6604 or via email at email@example.com For media inquiries, contact Wendy Ryan of Schwartz Communications at 781-684-0770, or via